Several studies have shown that the use of GnRH agonist for triggering of final oocyte maturation prevents the development of ovarian hyperstimulaion syndrome (OHSS), even in patients at high risk of developing OHSS [1]–[3]. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.